Friday, 13 December 2013

FDA Approves Abraxane Drug for Pancreatic Cancer

ABRAXANE® for Injectable Suspension: (paclitaxel protein-bound particles) for Injectable Suspension.
The albumin serves as a delivery vehicle, improving the transportation of the drug to the target cancer sites.The Food and Drug Administration (FDA) has recently approved the use of Abraxane in those patients suffering from end-stage pancreatic cancer. Based upon clinical trials, the novel drug should help to extend life expectancy and, hopefully, provide a better quality of life.

Paclitaxel is one of several cytoskeletal drugs hat target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks progression of mitosis, and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G-phase of the cell cycle without cell division.

No comments:

Post a Comment